Background
==========

The average human exome harbours around 20,000 single nucleotide variants (SNVs), of which approximately half are annotated as non-synonymous single nucleotide polymorphisms (nsSNPs) \[[@B1]\]. However, characterizing the functional consequences of nsSNPs by direct laboratory experimentation is both time consuming and expensive. Therefore, computational prediction algorithms capable of predicting and/or prioritizing putatively functional variants for further experimentation are becoming increasingly important.

There is a plethora of computational prediction algorithms capable of analysing the functional consequences of nsSNPs \[[@B2]\]. One of these methods is the Functional Analysis through Hidden Markov Models (FATHMM) algorithm \[[@B3]\]: a sequence-based method which combines evolutionary conservation in homologous (both orthologous and/or paralogous) sequences with 'pathogenicity weights', representing the overall tolerance of proteins (and their component domains) to mutations. Using our original weighting scheme (adjusted for inherited disease mutations), we observed an improved predictive performance over alternative computational prediction algorithms using a 'gold-standard' benchmark \[[@B4]\]. Nonetheless, these algorithms, including our own, were not designed to discriminate between nsSNPs influencing a specific disease (disease-specific) and other putative disease-causing/functional mutations (non-specific). For example, when tasked with discriminating between cancer-associated and other germline polymorphisms, these algorithms are capable of identifying a high proportion of cancer-promoting mutations. However, a large proportion of putative disease-causing (non-neoplastic) mutations are misclassified as having a role in carcinogenesis \[[@B5]\]. In both a clinical and a research context, these tools are commonly used to investigate the aetiology of specific diseases. We therefore believe that there is a significant need for disease-specific functional variant predictions.

To the best of our knowledge, computational prediction algorithms have been explored exclusively in a *gene-specific* manner, e.g. predicting the effects of nsSNPs in mismatch repair proteins \[[@B6],[@B7]\]. The sole context in which *disease-specific* predictions have been developed is in the prediction of cancer-associated mutations \[[@B8]-[@B11]\]. In our previous work, we adapted our original algorithm by means of a cancer-specific weighting scheme and observed improved predictive performances over alternative (cancer-specific) computational prediction algorithms when predicting the functional consequences of cancer-associated nsSNPs \[[@B12]\]. We have now extended this concept to a novel and more comprehensive 'disease-specific' weighting scheme to investigate whether such an approach is capable of prioritizing nsSNPs based on 17 disease concepts/categories.

Results
=======

In order to assess the potential benefits of making disease-specific predictions, we compared the performance of our disease-specific weighting scheme with the performance of our original algorithm (weighted for inherited disease mutations) and two (generic) computational prediction algorithms: SIFT \[[@B13]\] and PolyPhen-2 \[[@B14]\]. In our analysis, all generic prediction algorithms were found to be capable of discriminating between disease-causing mutations (i.e. both disease-specific and non-specific disease-causing mutations) and putative neutral polymorphisms (see Additional file [1](#S1){ref-type="supplementary-material"}: Supp. Info 1). However, our analysis showed that no distinction could be made between disease-specific and other non-specific disease-causing mutations when using these algorithms. For example, generic algorithms are incapable of discriminating between musculoskeletal-related variants and other disease-associated variants, thereby leading to high false positive rates (i.e. other disease-causing variants being incorrectly identified as being pathogenic with respect to musculoskeletal-related disease). On the other hand, it appears that a disease-specific approach to functional prediction is capable of distinguishing between disease-specific and other disease-causing mutations, thereby reducing the number of false positives identified and improving the overall performance of the algorithm. While our disease-specific approach is more specific than generic computational prediction algorithms, it would appear that this approach is also less sensitive. This general trend of greater specificity/less sensitivity was observed throughout the 17 disease concepts we tested (see Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}---data shown for musculoskeletal, developmental, endocrine and metabolic disorders; see Additional file [1](#S1){ref-type="supplementary-material"}: Supp. Info 2--18 for additional performance comparisons pertinent to the remaining disease concepts). These results illustrate the potential benefit of using a disease-specific approach to functional prediction when assessing nsSNPs in relation to specific diseases (by reducing the number of false positives identified); however, further work is needed to reduce the number of false negatives identified and improve sensitivity.

###### 

Performance of computational prediction algorithms when discriminating between disease-specific variants and other disease-causing/neutral variants

  **Algorithm**                  **tp**   **fp**   **tn**   **fn**   **Accuracy**   **Precision**   **Specificity**   **Sensitivity**   **NPV**   **MCC**   **AUC**
  ----------------------------- -------- -------- -------- -------- -------------- --------------- ----------------- ----------------- --------- --------- ---------
  Musculoskeletal                                                                                                                                               
   SIFT                          4,730    37,701   23,323    944         0.61           0.57             0.38              0.83          0.70      0.24      0.64
   PolyPhen-2                    5,278    44,047   34,859    714         0.66           0.61             0.44              0.88          0.79      0.36      0.71
   FATHMM                        5,902    51,596   29,202    201         0.66           0.60             0.36             *0.97*        *0.92*     0.41      0.73
   Disease-Specific              4,120    3,123    77,675   1,983       *0.82*         *0.95*           *0.96*             0.68          0.75     *0.66*    *0.93*
   Disease-Specific (20-fold)      \-       \-       \-       \-         0.80           0.92             0.94              0.66          0.74      0.63       \-
  Developmental                                                                                                                                                 
   SIFT                           845     41,586   23,983    284         0.56           0.54             0.37              0.75          0.59      0.12      0.56
   PolyPhen-2                     920     48,405   35,337    236         0.61           0.58             0.42              0.80          0.67      0.23      0.63
   FATHMM                        1,006    52,429   33,278    188         0.62           0.58             0.39             *0.84*        *0.71*     0.26      0.59
   Disease-Specific               621      710     84,997    573        *0.76*         *0.98*           *0.99*             0.52          0.67     *0.58*    *0.90*
   Disease-Specific (20-fold)      \-       \-       \-       \-         0.74           0.97             0.99              0.49          0.66      0.55       \-
  Endocrine                                                                                                                                                     
   SIFT                          3,084    39,347   23,443    824         0.58           0.56             0.37              0.79          0.64      0.18      0.60
   PolyPhen-2                    2,890    46,435   35,031    542         0.64           0.60             0.43              0.84          0.73      0.30      0.67
   FATHMM                        3,597    49,466   33,522    316         0.66           0.61             0.40             *0.92*        *0.83*     0.38      0.71
   Disease-Specific              2,392    1,015    81,973   1,521       *0.80*         *0.98*           *0.99*             0.61          0.72     *0.65*    *0.94*
   Disease-Specific (20-fold)      \-       \-       \-       \-         0.79           0.97             0.98              0.60          0.71      0.63       \-
  Metabolic                                                                                                                                                     
   SIFT                          10,731   31,700   21,913   2,354        0.61           0.58             0.41              0.82          0.69      0.25      0.64
   PolyPhen-2                    11,337   37,988   33,788   1,785        0.67           0.62             0.47              0.86          0.78      0.36      0.72
   FATHMM                        13,068   39,914   33,271    648         0.70           0.64             0.45             *0.95*        *0.91*     0.47      0.80
   Disease-Specific              10,767   3,209    69,976   2,949       *0.87*         *0.95*           *0.96*             0.78          0.82     *0.75*    *0.95*
   Disease-Specific (20-fold)      \-       \-       \-       \-         0.86           0.94             0.95              0.77          0.81      0.74       \-

![**Performance of disease-specific and generic computational prediction algorithms.** ROC curves for computational prediction algorithms when tasked with discriminating between disease-specific mutations and other germline variants (i.e. other disease-causing/neutral mutations).](1479-7364-8-11-1){#F1}

In the above, tp, fp, tn and fn refer to the number of true positives, false positives, true negatives and false negatives observed, respectively. Accuracy, precision, specificity, sensitivity, negative predictive value (NPV) and Matthew\'s correlation coefficient (MCC) were calculated using normalized numbers. Italic font corresponds to the best performing method for a given statistic.

As our weighting scheme was derived using the same mutation data used to assess our method (albeit using a leave-one-out analysis), we recognize the potential for bias. Therefore, we also performed a 20-fold cross-validation analysis (see Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Supp. Info 2--18). We observed no significant deviations in the performance measures reported and therefore concluded that the performance of our disease-specific approach is not an artefact of over-fitting. We also recognize that most of our algorithm\'s predictive power comes from our weighting scheme, i.e. it is the weighting scheme that allows us to differentiate between disease-associated variants and other disease-causing mutations. Therefore, we also compared our approach to a naive weighting scheme. Here, we used our weighting scheme (omitting sequence conservation) to derive a prediction score. Proteins, and their constituent domains, with a higher proportion of disease-associated mutations would predict all variants falling within them as *disease*, and those with a higher proportion of other disease-causing mutations/neutral polymorphisms would predict all variants as *neutral*. Overall, we observed a similar performance to that of our algorithm (see Additional file [1](#S1){ref-type="supplementary-material"}: Supp. Info 19--36). However, it should be noted that a naive approach is incapable of reliably discriminating between disease-associated mutations and other disease-causing variants as the weighting scheme becomes more balanced, whereas our disease-specific approach (which incorporates sequence conservation for prediction) appears to be less susceptible to balanced weights.

In order to facilitate the replication of our work, we have annotated SwissProt/TrEMBL disease variants (Release 2014_06) with the disease concepts used in our analysis and make this resource publically available at our website (<http://fathmm.biocompute.org.uk>). Using this dataset to train and test our algorithm, we observed similar performances to those reported above (see Additional file [2](#S2){ref-type="supplementary-material"}).

Discussion
==========

There is a plethora of computational prediction algorithms available to predict the functional consequences of nsSNPs \[[@B2]\]. However, these algorithms are not designed to distinguish between mutations related to a specific disease, or a group of related diseases (disease-specific), and other putative disease-causing (non-specific) mutations. As the cost of whole-exome/whole-genome sequencing falls, making these methods more amenable to use in a research or clinical context, the challenge of filtering true disease-causing candidate variants from other putative functional variants is likely to become increasingly important. In this work, we assessed the potential benefits of making disease-specific predictions (relevant to 17 disease categories) using the Functional Analysis through Hidden Markov Models (FATHMM) framework and observed an overall reduction in the number of false positives identified, thereby leading to improved specificity over traditional algorithms. However, we also observed an increase in the number of false negatives identified and conclude that additional work is needed to improve sensitivity and enhance the utility of our disease-specific approach. Nevertheless, there is potential to extend this approach to more specific categories for the purposes of enhancing clinical prediction.

An important consideration when evaluating the performance of computational prediction algorithms is the cross-validation dataset. Here, the performance of such algorithms should be trained and tested using different datasets (cross-validation). In order to alleviate the potential for bias in our results, we performed a 20-fold cross-validation procedure across our 17 disease concepts. From this analysis, we observed no significant deviations in the reported performance measures and therefore conclude that the performances observed were not an artefact of our disease-specific weighting scheme.

One of the major limitations of our disease-specific approach is that, in extreme cases, there is potential for dominating pathogenicity weights which could bias or exaggerate the effects of variants, e.g. when prioritizing variants in proteins and/or domains which have very strong associations with the disease concept under investigation. Here, the pathogenicity weights used could dominate the underlying amino acid probabilities (used to measure sequence conservation) and therefore bias the prediction. For example, when these weights are biased towards the disease concept, neutral polymorphisms falling within diverse regions of a protein/domain would be classified as 'damaging' as opposed to being classified as 'benign'. As a consequence, our disease-specific models are best suited as a whole-genome/whole-exome prioritization method (hypothesis-free) and should be used with caution when prioritizing variants in a gene-specific manner. In an attempt to alleviate the potential effects of dominating pathogenicity weights, measures of sequence conservation are presented alongside our rankings so that spurious predictions can be assessed and ignored.

An alternative approach to our disease-specific weighting scheme is to filter putative disease-causing nsSNPs using the Gene Ontology \[[@B15]\]. However, this approach is dependent upon protein annotations being made available whereas our algorithm does not require prior information on protein function. Furthermore, users adopting this approach are required to select from a range of technical phrases, e.g. 'negative regulation of cellular macromolecule biosynthetic process' (GO: 2000113). In contrast, our disease-specific models do not require any formal knowledge on GO terms and biological processes, just an understanding of which model/concept best represents the disease under investigation. Our disease-specific models, including a high-throughput web-based implementation of our algorithm and a standalone software package, are available at <http://fathmm.biocompute.org.uk>.

Methods
=======

Predicting the functional consequences of nsSNPs
------------------------------------------------

The procedure for predicting the functional consequences of nsSNPs has been described in Shihab et al. \[[@B3]\]. In brief, an *ab initio* hidden Markov model (HMM), representing the multiple sequence alignment of homologous (both orthologous and/or paralogous) sequences within the SwissProt/TrEMBL \[[@B16]\] database, is constructed using the HMMER3 \[[@B17]\] software suite. In conjunction, protein domains from the SUPERFAMILY \[[@B18]\] and Pfam (Pfam-A and Pfam-B) \[[@B19]\] databases are annotated onto the full-length protein sequence. If the mutation falls within an annotated region, then the corresponding model is extracted and used alongside our *ab initio* model. Next, our algorithm combines sequence conservation, within the most informative model (as measured by the Kullback-Leibler divergence \[[@B20]\] from the SwissProt/TrEMBL amino acid composition), with pathogenicity weights, representing the overall tolerance of the corresponding model to mutations (Equation 1).

$$\ln\frac{\left( {1.0 - \mathit{P}_{w}} \right)\left( {\mathit{W}_{n} + 1.0} \right)}{\left( {1.0 - \mathit{P}_{m}} \right)\left( {\mathit{W}_{d} + 1.0} \right)}$$

In Equation 1, *P*~w~ and *P*~m~ represent the probabilities for the wild-type and mutant amino acid residues, respectively, whereas *W*~d~ and *W*~n~ represent the relative frequencies of disease-associated and functionally neutral nsSNPs mapping onto the corresponding model, respectively. Here, we use inherited disease-causing nsSNPs annotated as DMs (damaging mutations) in the Human Gene Mutation Database (HGMD Pro 12.4 \[[@B21]\]) and putative neutral polymorphisms from the SwissProt/TrEMBL database \[[@B16]\] (Release 2013_04) to derive *W*~d~ and *W*~n~, respectively. The effect of our weighting scheme is as follows: when using pure conservation-based prediction methods, nsSNPs falling within diverse regions of the protein (or domain) are typically considered 'neutral/benign'. However, our weighting scheme assesses the tolerance of the corresponding model (representing a protein or domain) to mutation and then adjusts a conservation-based prediction accordingly. For example, nsSNPs falling within *P53* (a well-established cancer gene) are penalized according to the gene\'s intolerance to mutation whereas nsSNPs falling within *MHC* (known to contain hypervariable regions) are not penalized given the gene\'s apparent tolerance to mutation.

Incorporating a disease-specific weighting scheme
-------------------------------------------------

In order to derive a disease-specific weighting scheme, the phenotypes reported for inherited disease-causing nsSNPs listed as DMs (damaging mutations) in the Human Gene Mutation Database (HGMD Pro 12.4 \[[@B21]\]) were annotated using natural language processing against the Unified Medical Language System (UMLS \[[@B22]\]). These mutations were then grouped into 1 (or more) of 17 different root disease concepts, e.g. digestive disorders (\[[@B23]\] ---see Table [2](#T2){ref-type="table"} for the complete list). For disease-specific predictions, our original weighting scheme (see Equation 1) is replaced with the relative frequencies of disease-specific mutations and other non-specific disease-causing mutations/neutral polymorphisms mapping onto the model, i.e. our pathogenic training set consists of disease-causing mutations related to the disease concept whereas our neutral training set comprises all other disease-causing mutations (not related to the corresponding disease concept) and putative neutral mutations. This disease-specific weighting scheme has the same effect as our original weighting scheme (i.e. to penalize specific variants); however, this approach penalizes just those variants falling within disease-specific susceptible proteins or domains and treats other disease-causing mutations as neutral polymorphisms (with respect to the disease concept under investigation).

###### 

Summary of nsSNPs used in our disease-specific mutation datasets

  **Dataset**                            **Number of proteins**   **Number of amino acid substitutions**
  ------------------------------------- ------------------------ ----------------------------------------
  Human Gene Mutation Database (HGMD)                                                
   Blood                                           99                             1,474
   Blood coagulation                               45                             3,508
   Developmental                                  188                             1,199
   Digestive                                      116                             1,850
   Ear, nose and throat                           113                              943
   Endocrine                                      192                             3,913
   Eye                                            227                             3,031
   Genitourinary                                  166                             3,031
   Heart                                          247                             3,743
   Immune                                          75                             1,293
   Metabolic                                      485                             13,797
   Musculoskeletal                                309                             6,110
   Nervous system                                 473                             8,553
   Psychiatric                                    163                              747
   Reproductive                                    88                              883
   Respiratory                                     44                              775
   Skin                                           164                             3,183
  SwissProt/TrEMBL                                                                   
   Putative neutral polymorphisms                11,601                           37,488

Performance statistics
----------------------

In accordance with published guidelines \[[@B24]\], the following six parameters are used to assess the performance of our disease-specific models:

$${Accuracy} = \frac{{tp} + {tn}}{{tp} + {tn} + {fp} + {fn}}$$

$${Precision} = \frac{tp}{{tp} + {fp}}$$

$${Sensitivity} = \frac{tp}{{tp} + {fn}}$$

$${Specificity} = \frac{tn}{{fp} + {tn}}$$

$${NPV} = \frac{tn}{{tn} + {fn}}$$

$${MCC} = \frac{\left( {{tp} \cdot \mspace{9mu}{tn}} \right) - \left( {{fn}\mspace{9mu} \cdot {fp}} \right)}{\sqrt{\left( {{tp} + {fn}} \right)\left( {{tp} + {fp}} \right)\left( {{tn} + {fn}} \right)\left( {{tn} + {fp}} \right)}}$$

In the aforementioned data, tp and fp refer to the number of true positives and false positives reported, respectively, whereas tn and fn refer to the number of true negatives and false negatives reported, respectively. Receiver operating characteristic (ROC) and area under the curve (AUC) analyses were performed using the ROCR software suite \[[@B25]\].
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